WASHINGTON (dpa-AFX) - Hemispherx Biopharma (HEB) reported a full-year net loss of $9.0 million or $0.07 per share, narrower than last year's loss of $13.1 million or $0.10 per share.
This lower loss was aided by a fair value of revaluation of the estimated liability related to certain redeemable warrants resulting in a non-cash gain of $2.4 million in the year, compared to non-cash gain of $0.9 million last year.
Excluding the non-cash effects, the resultant net loss for the current year was approximately $11.4 million compared to $14.0 million last year.
Copyright RTT News/dpa-AFX
© 2012 AFX News
